Literature DB >> 12407143

Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient.

N Bodasing, R A Seaton, G S Shankland, A Pithie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12407143     DOI： 10.1093/jac/dkf206

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  10 in total

1.  Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study.

Authors:  Melissa D Johnson; Theo S Plantinga; Esther van de Vosse; Digna R Velez Edwards; P Brian Smith; Barbara D Alexander; John C Yang; Dennis Kremer; Gregory M Laird; Marije Oosting; Leo A B Joosten; Jos W M van der Meer; Jaap T van Dissel; Thomas J Walsh; John R Perfect; Bart-Jan Kullberg; William K Scott; Mihai G Netea
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

Review 2.  Oropharyngeal candidiasis in the era of antiretroviral therapy.

Authors:  George R Thompson; Payal K Patel; William R Kirkpatrick; Steven D Westbrook; Deborah Berg; Josh Erlandsen; Spencer W Redding; Thomas F Patterson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-02-13

Review 3.  Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis.

Authors:  Cristina Cunha Villar; Anna Dongari-Bagtzoglou
Journal:  Expert Rev Mol Med       Date:  2008-10-13       Impact factor: 5.600

4.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

5.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

6.  Noncanonical Fungal Autophagy Inhibits Inflammation in Response to IFN-γ via DAPK1.

Authors:  Vasilis Oikonomou; Silvia Moretti; Giorgia Renga; Claudia Galosi; Monica Borghi; Marilena Pariano; Matteo Puccetti; Carlo A Palmerini; Lucia Amico; Alessandra Carotti; Lucia Prezioso; Angelica Spolzino; Andrea Finocchi; Paolo Rossi; Andrea Velardi; Franco Aversa; Valerio Napolioni; Luigina Romani
Journal:  Cell Host Microbe       Date:  2016-11-23       Impact factor: 21.023

7.  The Aryl Hydrocarbon Receptor Governs Epithelial Cell Invasion during Oropharyngeal Candidiasis.

Authors:  Norma V Solis; Marc Swidergall; Vincent M Bruno; Sarah L Gaffen; Scott G Filler
Journal:  MBio       Date:  2017-03-21       Impact factor: 7.867

8.  Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series.

Authors:  Didier Payen; Valerie Faivre; Jordi Miatello; Jenneke Leentjens; Caren Brumpt; Pierre Tissières; Claire Dupuis; Peter Pickkers; Anne Claire Lukaszewicz
Journal:  BMC Infect Dis       Date:  2019-11-05       Impact factor: 3.090

Review 9.  Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.

Authors:  Derry K Mercer; Deborah A O'Neil
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

10.  Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series.

Authors:  Corine E Delsing; Mark S Gresnigt; Jenneke Leentjens; Frank Preijers; Florence Allantaz Frager; Matthijs Kox; Guillaume Monneret; Fabienne Venet; Chantal P Bleeker-Rovers; Frank L van de Veerdonk; Peter Pickkers; Alexandre Pachot; Bart Jan Kullberg; Mihai G Netea
Journal:  BMC Infect Dis       Date:  2014-03-26       Impact factor: 3.090
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.